Proteomics Instrument Market Booming as Demand for Advanced Diagnostics Soars, says Market.us

The field of life sciences has seen many significant developments in the last decade. One of these was the completion of the sequencing human genome. Next was the identification and quantification of human protein. This is a new branch of science that focuses on the analysis of gene expression at the level of the proteome. 

According to the latest report by Market.us,” The global Proteomics Instrument Market was valued at USD 29.8 billion in 2022 and is projected to reach USD 113.5 billion by 2032, at a CAGR of 14.3%.”

Anurag Sharma, senior research analyst at market.us said, “Proteomics Market Growth will be driven by rising demand for personalized medicine and the increase in advanced diagnostics tools used in targeted disease diagnosis and treatment. There is also an increasing emphasis on drug design, biomarker discovery, clinical diagnostics, and product usage for diagnosis and treatment.”

Because there is not much research in proteomics, the current state of proteomics has limited resources to address many issues, such as protein identification, quantification and characterization of post-translational modifications, structure and function elucidation, and possible interactions.

Market growth will be promoted by the increased emphasis on product attributes in drug development, biomarker discovery, and clinical diagnostics to diagnose and treat diseases. Market growth is being boosted by the protein research that has been done to treat COVID-19 patients. 

The increased investment in research and development in proteomics has been a growth driver. The National Institutes of Health (NIH), in the United States, funded $37 billion in biomedical research. This funding was provided to life sciences research that aimed to help identify biomarkers, which indicate the presence of disease or the gene/protein responsible.

In June 2022, researchers at the Indian Institute of Science Bangalore (IISc), created a new class of synthetic peptides. The mini-proteins can be used to kill viruses like SARS-CoV-2.

Agilent Technologies Inc. introduced Agilent Dako SARS/CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) in February 2021. This kit is intended to detect antibodies to SARS/CoV-2 in serum or plasma.

Thermo Fisher Scientific acquired Phitonex, Inc. in Dec 2020. This acquisition will allow Thermo Fisher Scientific to offer more flow cytometry capabilities and imaging multiplexing capabilities to better meet changing customer requirements in cell analysis research.

Proteomics is a key ingredient in the development of new drugs and vaccines as well as disease diagnosis. This is possible because of the use of multiple technologies such as chromatography, protein fractionation, X-ray crystallography, and spectroscopy. The cost of many instruments has increased, resulting in higher prices.

Mass spectrometers, for example, can cost between $20 Mn to $30 Mn. Many consumers might not want to spend on such expensive products, particularly for research organizations with limited resources and funding.

Market growth will be supported by increased investments by major players in advanced drugs and diagnostic tool production. In June 2021, Bruker Corp. introduced the two new timsTOF tools. It opens up new possibilities and applications such as epi proteomics/PTM characterization and deep multi-omic biomarker detection. They also facilitate and enhance these new applications in liquid biopsy research. These initiatives will likely boost the industry’s growth over the next few years.

North America is predicted to be the largest market for proteomics in the world with a large revenue share. It is also expected to prosper prominently over the analysis period. This is due to significant investments in structure-based drug design and extensive research on next-generation therapeutics. 

There has also been a growing demand for high-quality tools for the reproducibility of data. The focus on personalized therapies is increasing.